CBX-15 / Cybrexa Therap - LARVOL DELTA

Evaluation of antigen agnostic anti-tumor activity and immune memory induced by CBX-15 (alphalexTM-MMAE) in the rat. (PubMed, Immunotherapy) - "To our knowledge, this is the first work demonstrating both anti-tumor efficacy and induction of long-term anti-tumor immune memory by a tumor-selective drug in the rat, the species used for preclinical toxicological evaluation. This study provides a strong justification for exploring combination therapies with CBX-15 and other immunomodulators."

Journal • Preclinical • Breast Cancer • Oncology • CD4

Cybrexa Therapeutics Announces New Preclinical Data on Tumor-Selective Peptide-Drug Conjugates at ESMO Targeted Anticancer Therapies Congress 2025 (GlobeNewswire) - "The poster....highlighted preclinical results evaluating the efficacy, safety, and immune-modulating effects of alphalex conjugates across mouse and rat xenograft and syngeneic models, including colorectal, melanoma, renal, and breast cancers....Tumor-selective drug delivery: Plasma stability and in vivo analyses confirmed that alphalex conjugates selectively deliver microtubule inhibitors to tumor tissue while sparing healthy immune cells. Potent efficacy in multiple tumor models: Monotherapy: alphalex conjugates led to complete tumor suppression in HCT116 human colorectal cancer models. Combination therapy: In flank and metastatic models, alphalex PDCs demonstrated synergy with doxorubicin and anti-PD-L1 therapy, further enhancing tumor suppression."

Preclinical • Breast Cancer • Colorectal Cancer • Melanoma • Renal Cell Carcinoma

Cybrexa is progressing its broader pipeline, including CBX-15… (GlobeNewswire) - "Cybrexa is progressing its broader pipeline, including CBX-15, which is expected to enter the clinic in 2025 for the treatment of solid tumors using MMAE (monomethyl auristatin E) as its payload."

New trial • Oncology • Solid Tumor

Cybrexa Therapeutics to Debut Preclinical Data Demonstrating CBX-15 is Safe and Highly Efficacious in 13762 Triple Negative Breast Cancer Model at 35th AACR-NCI-EORTC Symposium (GlobeNewswire) - "Cybrexa Therapeutics...today announced it will present data findings on its preclinical candidate, CBX-15 (alphalex™-MMAE) for the treatment of triple negative breast cancer in a poster session at the 35th AACR-NCI-EORTC (ANE) Symposium. The event is taking place October 11-15, 2023, in Boston, Massachusetts....'In this preclinical study, CBX-15 demonstrated anti-tumor activity and efficacy without toxicity,'...These compelling data instill confidence and align with the Company’s strategy to progress CBX-15 to Phase 1 clinical trials in 1Q of 2024."

New P1 trial • Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Evaluation of antigen-agnostic anti-tumor activity and immunological memory induced by CBX-15 (alphalexTM-MMAE) in the rat syngeneic breast cancer model. (AACR-NCI-EORTC 2023) - No abstract available

Preclinical • Breast Cancer • Oncology • Solid Tumor